serinatherapeutics.com (SER): תחזית צמיחת רווח נקי למניה לשנה הבאה

The development of Serina Therapeutics, Inc. (SER) relies on the success of clinical trials and patent protection. The estimated EPS growth for the coming year shows a peak, after which the 28.90 level captures the current state. The company's strong pricing power is based on low-toxicity molecule delivery to the brain. The business is currently scaling its Parkinson's disease therapy, ensuring stable drug efficacy.
פילוחי מדדים ואנליטיקה של חברת Serina Therapeutics Inc (SER)

For Serina Therapeutics, Inc. (SER), the potential for royalty payments from the POZ platform directly determines future profitability, which is reflected in the consensus earnings forecast for the coming year. This indicator measures the percentage change in expected earnings per share, capturing real-time revisions to analyst models. By analyzing the historical trend of the n+1 earnings forecast, an investor assesses the stability of fundamental expectations, where any sharp reversal signals risks of failing to meet business targets.